首页> 外文OA文献 >P206 - Which patient population profits best from a high dose, once daily treatment with 3.0g mesalazine for maintaining clinical remission in ulcerative colitis? A subgroup analysis of a double-blind, double-dummy, randomised, controlled, dose-ranging study

【2h】

P206 - Which patient population profits best from a high dose, once daily treatment with 3.0g mesalazine for maintaining clinical remission in ulcerative colitis? A subgroup analysis of a double-blind, double-dummy, randomised, controlled, dose-ranging study

机译：P206 - 从高剂量中，哪种患者人口利润最佳，每天用3.0g甲烷嗪治疗，以维持溃疡性结肠炎的临床缓解症？双盲，双伪，随机，对照，剂量测量研究的亚组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
W. Kruis; L. Jonaitis; L. Kupcinskas; J. Pokrotnieks; G. Acute; T.L. Mikhailova; M. Horynski; M. Batovsky; Y.S. Lozinskii; I. Racz; K. Kull; A. Vcev; M. Faszczyk; R. Greinwald; R. Mueller;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Randomised clinical trial: A herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis - A double-blind, double-dummy study [J] . LanghorstJ., VarnhagenI., SchneiderS.B., Alimentary pharmacology & therapeutics. . 2013,第5期

机译：随机临床试验：与美沙拉嗪相比，没药，洋甘菊和咖啡炭的草药制剂可维持溃疡性结肠炎的缓解-双盲，双盲研究
2. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: A pooled analysis from two randomised controlled trials [J] . LichtensteinG.R., ZakkoS., GordonG.L., Alimentary pharmacology & therapeutics. . 2012,第2期

机译：使用其他5-ASA制剂的溃疡性结肠炎患者每天服用美沙拉嗪颗粒1.5 g维持缓解：来自两项随机对照试验的汇总分析
3. Mesalazine granules 1.5?g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials [J] . G. R. Lichtenstein, S. Zakko, G. L. Gordon, Alimentary Pharmacology & Therapeutics . 2012,第2期

机译：服用其他5-ASA制剂的溃疡性结肠炎患者每天服用1.5 mg的美沙拉嗪颗粒可缓解症状：来自两项随机对照试验的汇总分析
4. Synbiotic Therapy Significantly Reduces Molecular Markers of Inflammation and Clinical Scores in Patients with Active Ulcerative Colitis; A Randomised Controlled Trial [C] . Controlled Release Society annual meeting . 2004

机译：同步治疗显着减少了活性溃疡性结肠炎患者的炎症和临床评分的分子标记;随机对照试验
5. Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized double-blind study [O] . Haruhiko Ogata, Akihiro Ohori, Haruo Nishino, 2017

机译：每日一次剂量多药美沙拉嗪和多剂量美沙拉嗪维持溃疡性结肠炎缓解的疗效比较：一项随机双盲研究
6. P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study [O] . G R D’Haens, M C Dubinsky, M Regueiro, 2021

机译：P409维持患者缓解患者的无侵袭性预测因子，以严重的患者对汤法替尼治疗的严重活性溃疡性结肠炎，他每天两次从TOFACITINIB 10 mg减少至5毫克：6个月的双盲，随机铆接研究数据

P206 - Which patient population profits best from a high dose, once daily treatment with 3.0g mesalazine for maintaining clinical remission in ulcerative colitis? A subgroup analysis of a double-blind, double-dummy, randomised, controlled, dose-ranging study

著录项

相似文献

相关主题

期刊订阅